Loading organizations...
Seattle, Washington-based Dopl Technologies develops telerobotic and autonomous systems that enable healthcare specialists to perform remote diagnostic exams and medical procedures. The company's initial product is a telerobotic ultrasound system designed to deliver diagnostic care to rural hospitals and underserved communities within an estimated $20 billion beachhead market. Operating with a dedicated team of six employees, the startup recently raised $1.5 million in a 2025 pre-seed funding round led by venture capital firm TVF. Originating from early medical research conducted at the University of Washington, the firm has successfully tested prototypes across multiple hospitals and converted four letters of intent into active commercial contracts. The enterprise is currently seeking clearance from the FDA to officially launch its remote medical devices. Dopl Technologies was founded in 2018 by Ryan James, Steve Seslar, and Wayne Monsky.
Dopl Technologies has raised $2.3M across 2 funding rounds.
Dopl Technologies has raised $2.3M in total across 2 funding rounds.
Dopl Technologies has raised $2.3M across 2 funding rounds. Most recently, it raised $2.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2024 | $2M Seed | — | 305 Ventures, Andreessen Horowitz, Banana Capital, Mark Kahn, Chingona Ventures, First Round Capital, FTX Ventures, MS&AD Ventures, Precursor Ventures, SV Angel, Techstars, Y Combinator, Saxon Baum | Announced |
| Aug 1, 2022 | $270K Seed | — | Hustle Fund, Precursor Ventures, Techstars | Announced |
Dopl Technologies has raised $2.3M in total across 2 funding rounds.
Dopl Technologies's investors include 305 Ventures, Andreessen Horowitz, Banana Capital, Mark Kahn, Chingona Ventures, First Round Capital, FTX Ventures, MS&AD Ventures, Precursor Ventures, SV Angel, Techstars, Y Combinator.
Dopl Technologies is a Seattle-based medtech startup developing a telerobotic ultrasound system powered by AI and robotics to democratize access to diagnostic exams and interventional procedures, particularly in underserved and rural communities.[1][2][3] Their first product, an intelligent ultrasound system, enables remote specialists to perform scans via robotic arms, reducing scan times through automation and addressing workforce shortages, geographic barriers, and provider retirements affecting 60 million U.S. residents.[2][3][4] With six employees and $1.5 million raised in pre-seed funding in 2025, the company targets a $20 billion market for earlier disease diagnoses while pursuing FDA clearance for a 2026 launch.[3]
Dopl Technologies was co-founded in 2022 by Ryan James, PhD (CEO/CTO, ex-Microsoft engineer), Steve Seslar, MD, PhD (COO), and Wayne Monsky, MD, PhD (CMO, Harvard-trained specialists), building on research started in 2017 at the University of Washington.[3][4][5] The trio explored novel care delivery methods, conducting in vitro and in vivo remote robotic procedures, stakeholder workshops, and pilots like a 2021 collaboration with Ocean Beach Hospital for cardiac ablation and tele-robotic cardiac ultrasound.[4] Pivotal early traction came from recognizing urban-rural care gaps, leading to Dopl's formation to bridge them via telerobotics, with ongoing partnerships like Ocean Beach Hospital aiding FDA pursuits.[3][4]
Dopl rides the convergence of AI, robotics, and telehealth trends accelerating post-pandemic, where remote care addresses U.S. healthcare disparities amid provider shortages and rural access gaps.[2][3][4] Timing aligns with rising demand for automated diagnostics in a $20B ultrasound sector strained by geography and demographics, amplified by AI efficiencies in imaging.[2][3] Market forces like aging populations, telehealth reimbursements, and robotics adoption (e.g., in surgery) favor them, while their UW-honed innovations influence ecosystems by piloting scalable models for rural hospitals, potentially standardizing telerobotics for broader procedures.[3][4]
Dopl's path forward hinges on FDA clearance for commercial rollout in 2026, scaling ultrasound distribution, and expanding to interventional procedures amid $1.5M-funded growth.[3] Trends like AI automation in diagnostics and remote robotics will propel them, especially as workforce crises deepen, evolving their influence from rural pilots to ecosystem-wide care equity.[2][3][4] With strong backing and validation, they stand to transform access, echoing their founding vision of high-quality care everywhere.[2]
